latest news releases from the newsroom
Momenta Pharmaceuticals Presents Preclinical Data for Novel Anticoagulant M118 At American College of Cardiology
NEW ORLEANS, March 26, 2007 (PRIME NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the company's novel engineered heparin, M118, demonstrated superior efficacy to a standard dose of unfractionated heparin (UFH) in an animal model of acute arterial thrombosis. The electrolytic injury model mimics the physiological response that occurs following the rupture of an atherosclerotic plaque in a coronary artery, and indicates the potential for M118 to be used in patients diagnosed with acute coronary syndromes (ACS). The data was presented today at the American College of Cardiology's (ACC) 56th Annual Scientific Session.
InRob Tech Ltd.
InRob Signs Maintenance and Service Contract With High-Power Rectification Systems Manufacturer
LAS VEGAS, March 26, 2007 (PRIME NEWSWIRE) -- InRob Ltd. ("InRob") (OTCBB:IRBL), a leader in the development and production of advanced wireless control systems and integrated solutions for unmanned ground vehicles (UGV), today announced that it has signed an agreement to provide maintenance and customer services to Amin Bakara, a developer and manufacturer of power packs, chargers, inverters, high-power rectification and other related systems to major defense clients in Israel.
Northrop Grumman Corp.
Northrop Grumman Achieves Record 37th CMMI Level 5 Rating
SAN DIEGO, March 26, 2007 (PRIME NEWSWIRE) -- Northrop Grumman Corporation (NYSE:NOC) has achieved its 37th Software Engineering Institute Capability Maturity Model Integration (CMMI(r)) Level 5 rating, the highest possible rating for benchmarking commercial and defense industry best practices for management and engineering.